Forget Centessa Pharmaceuticals: This Rare‑Disease Specialist Has a Superior Portfolio and Pipeline

Over the past year, shares of Centessa Pharmaceuticals (NASDAQ: CNTA) have significantly outperformed broader equities as the biotech has made tremendous progress with a promising pipeline candidate. However, it's worth wondering whether the drugmaker still has significant upside left after this run. Maybe it does, but before buying shares of Centessa, investors should consider another larger, well-established biotech with (arguably) much better prospects: Vertex Pharmaceuticals (NASDAQ: VRTX). Will AI c ...